查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球脫髮藥物市場 - 2022-2029
市場調查報告書
商品編碼
1140714

全球脫髮藥物市場 - 2022-2029

Global Alopecia Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

脫髮治療市場預計將在 2021 年達到 82.4 億美元，到 2029 年達到 148 億美元，在預測期間(2022-2029 年)以 8.0% 的複合年增長率增長。

脫髮是指部分或全部毛髮脫落，尤其是頭皮、整個頭部或全身毛髮。分為斑禿、男性型禿髮、斑禿、牽引性禿髮、斑禿、斑禿等類型。它可能是由遺傳、荷爾蒙變化、醫療狀況或衰老的正常部分引起的。藥物、頭髮移植和激光治療用於治療脫髮。

市場動態

脫髮治療市場 慢性疾病如急性應激障礙、多囊卵巢疾病 (pcod)、甲狀腺機能亢進、甲狀腺機能減退、癌症、狼瘡、垂體功能減退症的患病率越來越高 背景是我們正在做的事情。

脫髮患病率的增加和脫髮治療研發活動的增加預計將推動市場增長

隨著煙草和酒精消費量增加導致脫髮患病率增加，市場對脫髮治療的需求不斷增加。有幾個因素會導致脫髮，包括衰老和荷爾蒙失調。急性應激障礙、多囊卵巢病 (PCOD)、甲狀腺功能亢進、甲狀腺功能減退、癌症、狼瘡、垂體功能減退等慢性疾病的患病率增加似乎將刺激市場增長。

針對脫髮治療藥物的研發活動正在加緊。預計新療法的批准將刺激市場增長。例如，2020 年 7 月，Concert Pharmaceuticals, Inc. 的口服 Janus 激□抑製劑 CTP-543 獲得了突破性治療指定，用於治療成人中重度斑禿患者。該臨床試驗表明，CTP-543可用於中度至重度斑禿患者。患者接受 CTP-543 8 mg 每天兩次或 12 mg 每天兩次。 CTP-543 與安慰劑相比，在第 24 周根據脫髮嚴重程度工具 (SALT) 測量的基線相對變化□50% 的患者中顯示出統計學上的顯著差異，主要達到了評估項目。 CTP-543 一般耐受性良好。患者中僅報告了 1 起嚴重的不良事件。

2020 年 3 月，禮來公司獲得了美國食品藥品監督管理局 (FDA) 授予的用於治療斑禿的巴瑞替尼的突破性療法認定。 Baricitinib 是一種每日一次的口服 JAK 抑製劑。 varicitinib 在斑禿患者中的 II 期臨床試驗顯示沒有嚴重的不良事件，也沒有新的安全信號。此外，僅觀察到輕度或中度治療不良事件。

多個組織、團體和研究機構參與了對脫髮管理和治療的研究。例如，國家斑禿基金會 (NAAF) 是一個致力於提高人們對斑禿的認識的非營利組織。 NAAF 支持研究以尋找治療斑禿的治療方法和可接受的治療方法，支持患有該疾病的患者，並對公眾進行有關斑禿的教育。該組織提供支持、意識和宣傳、研究以尋找治療或治愈斑禿的方法。

輕微和嚴重的藥物副作用阻礙市場增長

2020年，根據以臨床為中心的藥學刊物American Pharmacists，他們發表了一篇文章——雄激素性脫髮的治療選擇，用於治療雄激素性脫髮的藥物有很多副作用。例如，局部使用米諾地爾可引起局部紅斑和瘙癢，以及水腫(腫脹)、面部毛髮過度生長、頭髮變色、心動過速和乳房疼痛等副作用。口服非那雄胺可引起頭暈和體位性低血壓。這些是市場增長的主要障礙。

行業分析

全球脫髮治療市場根據波特五力、監管分析、供應鏈分析和定價分析、報銷分析和未滿足的需求等各種行業因素對市場進行了深入分析。

細分分析

預計斑禿細分市場將佔據全球脫髮治療市場最大的市場份額

由於斑禿的高患病率，斑禿細分市場佔有率最高。根據美國斑禿協會的數據，全世界約有 1.47 億人患有斑禿。斑禿表現為頭皮上離散的、光滑的脫髮斑塊。它也可能發生在其他有頭髮的區域，例如眉毛、睫毛、鬍鬚和四肢。斑禿常見於自身免疫性疾病患者，即唐氏綜合症、糖尿病和甲狀腺功能亢進症患者。斑禿也可發展為普禿或全禿。幾家公司專注於開發治療斑禿的療法。作為斑禿的治療方法，存在一條有希望的管道。例如，2019 年 1 月，輝瑞日本公司開始了其口服 JAK3 抑製劑 PF-06651600 的 2/3 期試驗，用於治療中度至重度斑禿患者。

按地區分析

北美在全球脫髮藥物市場中佔有最大的市場份額。

由於脫髮的高患病率，北美在脫髮藥物市場佔據主導地位。根據全國斑禿的數據，美國約有 680 萬人患有斑禿。根據美國脫髮協會的數據，大約 95% 的男性脫髮是由男性型脫髮引起的。一些公共和私營公司正在為治療脫髮的新療法的研發活動籌集資金。正在進行技術創新以開發治療脫髮的療法。急性應激障礙、多囊卵巢病 (pcod)、甲狀腺功能亢進、甲狀腺功能減退、癌症、狼瘡和垂體功能減退症的高患病率預計將刺激市場增長。

競爭格局

由於存在多個國際和區域參與者，脫髮治療市場是一個競爭激烈的市場。疾病多樣化、技術進步、收入獲取和機會正在加劇市場競爭。 Aclaris Therapeutics, Cipla, Concert Pharmaceuticals, Daiichi Sankyo, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Company, Sun Pharmaceutical Industries 等等。 Inc.、Sun Pharmaceuticals Industries Ltd. 是市場份額較大的主要參與者。

公司利用產品開發、研發、技術進步和市場擴張戰略來維持其市場地位。例如，2020 年 6 月，Follica, Inc. 宣布已成功完成治療男性型脫髮男性脫髮的安全性和有效性優化研究，並準備將其主導項目推進到 III 期開發。正在進行中，並在與美國食品和藥物管理局 (FDA) 的會議上收到了積極的反饋。

  • 2019 年 12 月，Follica, Inc. 公佈了一項針對治療男性型脫髮的安全性和有效性優化研究的主要結果。該研究旨在選擇結合 Follica 專有設備和外用藥物的最佳治療方案，成功實現了其主要終點。與治療 3 個月後的基線相比，這種治療顯示可見毛髮數量有統計學意義的 44% 改善。此外，與基線相比，治療 3 個月後可見毛髮數量的總體改善為 29%，表明最佳治療方案的結果顯著改善。
  • 2021 年 8 月，開發免疫炎性疾病新候選藥物的臨床階段生物製藥公司 Aclaris Therapeutics, Inc. 與禮來 (Eli Lilly) 公司簽訂了治療斑禿的非獨家專利許可協議。宣布它已將 Aclaris 許可的與使用禮來公司的 JAK 抑製劑 varicitinib 相關的專利的某些權利轉讓給禮來公司。

值得關注的重點公司

Aclaris 治療公司：

概述 Aclaris 療法是一家臨床階段的生物製藥公司，正在開發一系列新型皮膚病學和免疫炎症療法。成立於2009年，總部位於美國賓夕法尼亞州。

產品組合

XELJANZ：一種口服藥物，可在標籤外開具治療斑禿的處方。也稱為託法替尼。它未經 FDA 批准可用於治療頭髮稀疏。

重大進展。 2022 年 8 月，Aclaris 宣布與禮來(Lilly)就斑禿達成專利許可協議。

全球脫髮治療市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁內容。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 脫髮患者增加
      • 啟動脫髮治療的研發活動
    • 限制因素
      • 輕微和嚴重的藥物副作用
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 監管分析
  • 供應鏈分析
  • 定價分析
  • 保險報銷分析
  • 未滿足的需求分析

第6章按疾病類型

  • 男性型禿髮
  • 斑禿
  • 瘢痕性脫髮
  • 牽引性脫髮
  • 全身脫髮
  • 原發性脫髮
  • 其他

第 7 章性別

  • 男
  • 女性

第 8 章按藥物類型

  • 外部代理
    • 米諾地爾
    • 非那雄胺
  • 腎上腺皮質類固醇
  • 免疫抑製劑
    • 環孢素
  • 其他

第 9 章給藥途徑

  • 口語
  • 外用
  • 注入

第十章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 13 章公司簡介

  • Aclaris Therapeutics Inc.
    • 公司概況
    • 表格組合和說明
    • 主要亮點
    • 財務摘要
  • Cipla Inc.
  • Concert Pharmaceuticals Inc
  • Daiichi Sankyo Inc
  • GlaxoSmithKline PLC
  • HCell Inc.
  • Johnson & Johnson
  • Merck & Co. Inc
  • Sun Pharmaceuticals Industries Ltd
  • Lexington Intl., LLC

第14章 全球脫髮治療市場-DataM

簡介目錄
Product Code: DMPH2578

Market Overview

Alopecia Treatment Market was valued US$ 8.24 billion in 2021 and is estimated to reach US$ 14.8 billion by 2029, growing at a CAGR of 8.0% during the forecast period (2022-2029).

Alopecia is the partial or complete loss of hair, especially on the scalp, entire head, or the entire body. It is classified into different types as the alopecia areata, androgenic alopecia, alopecia totalis, traction alopecia, alopecia Universalis, and cicatricial alopecia. It occurred due to heredity, hormonal changes, medical conditions, or a normal part of aging. Drugs, hair transplants, and laser therapy are used for the treatment of Alopecia.

Market Dynamics

The alopecia treatment market is driven by the growing prevalence of chronic diseases, such as acute stress disorder, polycystic ovary disease (pcod), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism.

Increasing prevalence of alopecia and rising R&D activities for alopecia therapy are expected to drive market growth

The market is driven by the increasing demand for alopecia treatment with the increasing prevalence of alopecia due to the increasing consumption of tobacco and alcohol. Several factors, such as aging and hormonal anomalies, lead to the development of Alopecia. The growing prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism, shall stimulate market growth.

There is increasing research and development activities for the development of Alopecia therapies. The expected approval of emerging therapies shall stimulate market growth. For instance, in July 2020, Concert Pharmaceuticals, Inc. had received the Breakthrough Therapy Designation for the oral Janus kinase inhibitor, CTP-543, to treat adult patients with moderate-to-severe alopecia areata. The clinical trial has demonstrated that the use of the CTP-543 among patients with moderate-to-severe alopecia areata. The patients were treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543. CTP-543 has met the primary efficacy endpoint with statistically significant differences relative to placebo in the patients achieving a ≥ 50% relative change from baseline at 24 weeks as measured by the Severity of Alopecia Tool (SALT). CTP-543 was generally well tolerated. Only one serious adverse event was reported among the patients.

In March 2020, Eli Lilly had received the breakthrough therapy designation from the United Food and Drug Administration (FDA) for baricitinib to treat alopecia areata. Baricitinib is the once-daily oral JAK inhibitor. The Phase II trial of the baricitinib conducted among the patients with the alopecia areata demonstrated no new safety signals with no serious adverse events. Only mild or moderate treatment-emergent adverse events (TEAEs) were observed among the patients.

Several organizations, associations, and institutes are involved in researching the management and treatment of alopecia. For instance, The National Alopecia Areata Foundation (NAAF) is a non-profit organization involved in raising awareness regarding the alopecia areata. NAAF supports research to find a cure or acceptable treatment for alopecia areata, supports those with the disease, and educates the public about alopecia areata. This organization provides support, awareness & advocacy, and research to find a treatment or cure for alopecia.

Minor & Major side effects of drugs is likely to hinder the market growth

According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2020 that medication used for the treatment of androgenetic alopecia has many side effects. For example, topical minoxidil can cause local erythema and pruritus and also some side effects like Edema (swelling), excessive hair growth on face, hair discoloration, tachycardia, breast pain. Oral drug finasteride can cause dizziness, orthostatic hypotension and others. These are the major restricting factors of the market growth.

Industry Analysis

The global alopecia treatment market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis and pricing analysis, reimbursement analysis, unmet needs.

Segment Analysis

Alopecia areata segment is expected to hold the largest market share in global alopecia treatment market

The alopecia areata segment accounts for the highest market due to the high prevalence of alopecia areata. According to the National Alopecia Areata, approximately 147 million people are affected by alopecia areata worldwide. Alopecia areata is presented with discrete, smooth patches of alopecia on the scalp. It also occurs in other hair-bearing areas, such as the eyebrows, eyelashes, beard, and extremities. Alopecia areata is prevalent among patients with autoimmune diseases, i.e., Down's syndrome, diabetes, and hyperthyroidism. It can progress into the alopecia Universalis and totalis. Several companies are focusing on developing therapies for the treatment of Alopecia Areata. There is the presence of a promising pipeline for the treatment of Alopecia Areata. For instance, in January 2019, Pfizer Inc. had initiated the Phase II/III trial of oral JAK3 inhibitor, PF-06651600, to treat patients with moderate to severe alopecia areata.

Geographical Analysis

North America region holds the largest market share in the global alopecia treatment market

North America dominated the alopecia treatment market due to the high prevalence of alopecia. According to the National Alopecia Areata, approximately 6.8 million people are affected by alopecia areata in the United States. According to the American Hair Loss Association, approximately 95% of hair loss occurred due to androgenetic alopecia among men. Several public and private companies raise the investment for the research and development activities for the novel therapies to treat alopecia. There is growing innovation for the development of therapies for the treatment of alopecia. The high prevalence of acute stress disorder, polycystic ovary disease (pcod), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism shall stimulate market growth.

Competitive Landscape

The alopecia treatment market is highly competitive with the presence of several international and local market players. Disease diversification, technological advancement, revenue generation, and opportunities intensify the market competition. Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., and Sun Pharmaceuticals Industries Ltd are the leading market players with significant market share.

Companies are using product development, research and development, technology advancement, and market expansion strategies for holding their position in the market. For instance, in June 2020, Follica, Inc. had received positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase III development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

  • In December 2019, Follica, Inc. had announced the topline results from its safety and efficacy optimization study to treat hair loss in male androgenetic alopecia. The study was designed to select the optimal treatment regimen using Follica's proprietary device combined with a topical drug and successfully met its primary endpoint. The treatment regimen demonstrated a statistically significant 44% improvement of visible hair count after three months of treatment compared to baseline. The overall improvement of visible hair count after three months of treatment was 29% compared to baseline, and a substantially improved outcome was seen with the optimal treatment regimen.
  • In Aug 2021, Aclaris Therapeutics, Inc. a clinical-stage biopharma company that develops new drug candidates for immuno-inflammatory diseases, announced its non-exclusive patent license agreement with Eli Lilly and Company by which Aclaris gave some rights to Lilly under patents that Aclaris licences for usage of JAK inhibitor of Lilly baricitinib for Alopecia areata treatment.

Key Companies to Watch

Aclaris therapeutics Inc:

Overview: Aclaris therapeutics is clinical stage biopharma company that develops novel dermatological therapies and pipeline of drugs for immune-inflammatory diseases. It was founded in 2009 and is headquartered in Pennsylvania, United States.

Product Portfolio:

XELJANZ: It is the oral medicine that can be prescribes off label for alopecia areata treatment. It is also known as Tofacitinib. It is not FDA approved medicine for hair loss.

Key Developments: In Aug 2022, Aclaris announced its patent licence agreement for alopecia areata with Lilly.

The global alopecia treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Increasing prevalence of alopecia
      • 4.1.1.2. Rising R&D activities for alopecia therapies
    • 4.1.2. Restraints:
      • 4.1.2.1. Minor & Major side effects of drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Regulatory Analysis
  • 5.3 Supply Chain Analysis
  • 5.4 Pricing Analysis
  • 5.5 Reimbursement Analysis
  • 5.6 Unmet Needs

6. By Disease Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 6.1.2. Market Attractiveness Index, By Disease Type
  • 6.2. Androgenic Alopecia
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, USD Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. Alopecia Areata
  • 6.4. Cicatricial Alopecia
  • 6.5. Traction Alopecia
  • 6.6. Alopecia Totalis
  • 6.7. Alopecia Universalis
  • 6.8. Others

7. By Gender

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 7.1.2. Market Attractiveness Index, By Gender
  • 7.2. Male
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Female

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 8.1.2. Market Attractiveness Index, By Gender
  • 8.2. Topical Agents
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Minoxidil
    • 8.2.4. Finasteride
  • 8.3. Corticosteroids
  • 8.4. Immunosuppressants
    • 8.4.1. Cyclosporine
  • 8.5. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Topical
  • 9.4. Injectable

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, USD Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. The U.S.
      • 11.2.8.2. Canada
      • 11.2.8.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. The U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. Australia
      • 11.5.8.5. Rest of Asia Pacific
  • 11.6. The Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Aclaris Therapeutics Inc
    • 13.1.1. Company Overview
    • 13.1.2. Form Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Cipla Inc.
  • 13.3. Concert Pharmaceuticals Inc
  • 13.4. Daiichi Sankyo Inc
  • 13.5. GlaxoSmithKline PLC
  • 13.6. HCell Inc.
  • 13.7. Johnson & Johnson
  • 13.8. Merck & Co. Inc
  • 13.9. Sun Pharmaceuticals Industries Ltd
  • 13.10. Lexington Intl., LLC

LIST NOT EXHAUSTIVE

14. Global Alopecia Treatment Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Method of Fixation
  • 14.3. Contact Us